StockIQ.techStryker Corporation (SYK) Stock Analysis
Free AI-powered analysis and research for Stryker Corporation stock
Sector: Healthcare
SYK snapshot
Data as of 3 Nov 2026 close. Updated daily.
Stryker Corporation scores 69/100 on StockIQ's model, which reads as positive signals overall. The price is below its 200-day average and at 34% of its 52-week range, down 13.8% over the past year. Latest reported figures show a profit margin of 14.4%, return on equity of 16.5% and revenue growth of +9.4%.
What is driving the score
- RSI Neutral: +5
- Strong Uptrend: +10
- MACD Bullish: +8
- High P/E (31.5): -10
- Good Profit Margin (14.4%): +5
- Strong Liquidity (2.16 Current Ratio): +8
- Strong ROE (16.5%): +5
- Below MA200: -4
- Underperforming (-13.8% over 1 year): -5
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full SYK report
Stryker Corporation (SYK) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze SYK Now →📰 Latest Update
Stryker (SYK) Stock Fair Value Falls After Analysts Reset Expectations Following Q3 Guidance
Sun, November 1, 2026 at 12:19 AM UTC 2 min read
Stryker's fair value has decreased from approximately US$369 to US$351 following Q3 guidance, reflecting analysts' lowered expectations amid ongoing manufacturing issues in the Peripheral Vascular unit. Despite this, several firms maintain positive ratings on the stock, highlighting its long-term potential and quality as a MedTech company. However, concerns about execution challenges and recent disruptions have led some analysts to adopt a more cautious stance.